Vor Biopharma (VOR) investor relations material

Executive summary

• Focused on developing telitacicept, a dual-target fusion protein for autoimmune diseases, with global Phase 3 trials underway for gMG and SjD outside Greater China and topline results for gMG expected in 1H27.

• Telitacicept received its fourth and fifth commercial approvals in China for Sjögren's disease and IgA nephropathy.

• Phase 3 TELIGAN trial results in IgA nephropathy were published in The New England Journal of Medicine.

• Net loss for Q2 2026 was $62.8M, a significant improvement from $1.57B in Q2 2025, mainly due to prior year one-time license expenses and warrant liability changes.

• Cash, cash equivalents, and marketable securities totaled $466.1M as of June 30, 2026, expected to fund operations into early 2029.

Financial highlights

• Q2 2026 research and development expenses were $25.9M, down from $261.5M in Q2 2025, reflecting the absence of a $222.6M license charge and lower facility and severance costs.

• General and administrative expenses rose to $21.9M in Q2 2026 from $12.8M in Q2 2025, driven by higher stock-based compensation and commercial preparation costs.

• Net loss per share for Q2 2026 was $1.16, compared to $251.24 in Q2 2025, reflecting the impact of the reverse stock split and improved operating results.

• For the six months ended June 30, 2026, net cash used in operating activities was $63.6M, with $74.8M provided by financing activities, mainly from a private placement.

• Additional $48.4M was raised in July 2026, further extending the cash runway.

Outlook and guidance

• Cash runway is projected into early 2029, assuming current operating plans and no major changes in clinical development pace or scope.

• Topline data from the global Phase 3 gMG trial is expected in the first half of 2027; the SjD trial is actively enrolling.

• Ongoing global development of telitacicept in major autoimmune indications to support potential regulatory approvals in the US, Europe, and Japan.

• Additional capital will be needed for future expansion, commercialization, or if development timelines accelerate.